retatrutide mechanism triple agonist A review of an investigational drug retatrutide, a novel agent for the treatment of obesity | European Journal of Clinical Pharmacology Triple Agonist Peptides Explained: Retatrutide,

Common early side effects like nausea and reduced appetite are usually mild to moderate and tend to diminish as your body adapts

Therefore, its important to talk to a healthcare provider before starting any OTC treatments

GLP-1 medications are not safe for everyone

Specific dose levels and titration schedules varied between study arms and are defined within each trial protocol

What Medical Spas and Aesthetic Providers Should Know While the FDA announcement did not specifically address medical spas, the agencys stated concerns apply broadly to any entity marketing compounded GLP-1 products: Compounded GLP 1s are not FDA approved and cannot be presented as equivalent to approved products